Intra-Cellular Therapies (ITCI) Competitor Comparison
We are evaluating the key criteria listed to compare Intra-Cellular Therapies (ITCI) against its competitors in the Biotechnology industry.
Market Capitalization
27 / 368Gross Profits
47 / 278Total Revenue
26 / 300EBITDA
267 / 337Free Cashflow
291 / 352Quick Ratio
167 / 357Earnings per Share
115 / 359Dividend yield
0 / 6Total Cash
62 / 358Performance 3 years
42 / 368Performance 5 years
10 / 368Performance 10 years
20 / 368Linearity 3 years
239 / 368Linearity 5 years
366 / 368Linearity 10 years
362 / 368Total Rank
165 / 368Dividend Rank
169 / 368Valuation Rank
210 / 368Piotroski Rank
34 / 368Muliplier Rank
126 / 368Performance 10 years - ITCI ranking 20 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.